Skip to content
EdvinceEdvince
  • AboutExpand
    • About
    • Lars Edvinsson
    • Board of directors
    • Management
    • Scientific advisory board
  • Research & developmentExpand
    • Pioneering research
    • Mechanism of action
    • EDV2209
    • Results – Completed phase 1b/2a study
    • Clinical and regulatory path forward for the Phase 2b SAH study
    • Orphan Drug
    • Publications
    • Collaborative partners
  • PipelineExpand
    • Pipeline
    • SAH – Subarachnoid haemorrhage
    • FI – Focal ischemic stroke
    • GI – Global cerebral ischemia
  • InvestorsExpand
    • Strategy
    • Milestones
    • Market Overview
    • Patent
    • Shareholders
    • News
EdvinceEdvince

Investor information

Strategy
Milestones
Market Overview
Patent
Shareholders
Edvince

Contact

Medicon Village
223 81 Lund. Sweden
info@edvince.com

© 2026 Edvince | Privacy Policy

  • About
    • About
    • Lars Edvinsson
    • Board of directors
    • Management
    • Scientific advisory board
  • Research & development
    • Pioneering research
    • Mechanism of action
    • EDV2209
    • Results – Completed phase 1b/2a study
    • Clinical and regulatory path forward for the Phase 2b SAH study
    • Orphan Drug
    • Publications
    • Collaborative partners
  • Pipeline
    • Pipeline
    • SAH – Subarachnoid haemorrhage
    • FI – Focal ischemic stroke
    • GI – Global cerebral ischemia
  • Investors
    • Strategy
    • Milestones
    • Market Overview
    • Patent
    • Shareholders
    • News